SEC Form 4 · accession 0001757072-26-000007
Evommune, Inc. · EVMN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kyle Carver
Officer — Chief Financial Officer
Period of report
Jul 8, 2026
Accepted (ET)
Jul 10, 2026 · 7:59 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0002044725
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 8, 2026 | P | 1,000 | $13.26 | A | 60,335 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The purchase by the reporting person reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934 with the sales of 1,000 shares of the Issuer's common stock by the reporting person at the price of $23.42 per share on May 28, 2026. The reporting person has agreed to pay to the Issuer upon settlement of the purchase, $10,160, representing the full amount of the profit realized in connection with the short-swing transaction.